Clinical trial documentation
Home > SCRS 2026 Prize Draw Winner Announcement

SCRS 2026 Prize Draw Winner Announcement

Akesa is pleased to announce the winner of its SCRS 2026 Conference Prize Draw.

Thank you to everyone who visited the Akesa booth at SCRS 2026 and participated in our survey regarding the sourcing and management of clinical trial medications. We greatly appreciate the valuable insights shared by clinical research professionals across the industry.

Following the completion of the prize draw, we are pleased to confirm that the recipient of the $1,000 Luxury Escapes Gift Voucher is:

P. Patel (NSW)

The winner was selected through a random draw conducted in accordance with the promotion’s terms and conditions.

Akesa congratulates P. Patel on receiving the prize and thanks all participants for taking the time to contribute their feedback.

The information provided by participants helps Akesa better understand the challenges faced by research sites and supports our ongoing efforts to improve services for the clinical trials community across Australia, New Zealand, and the broader Asia-Pacific region.

We look forward to connecting with many of you again at future industry events.


Prize: $1,000 Luxury Escapes Gift Voucher
Promotion: Akesa SCRS 2026 Conference Prize Draw
Winner: P. Patel (NSW)


Author

Nicholas Brittain - Chief Operating Officer, Akesa

Nicholas Brittain

Chief Operating Officer

  • Clinical trials in Australia: the real advantage

    Australia competes on speed, data quality, and a cash rebate, not on being the cheapest option. Understanding what that combination does, and does not, deliver is a strategic question.

  • Beyond reimbursement: Why managed access programs are becoming essential to patient access in Australia

    Scientific innovation is changing the shape of medicine access. Precision therapies, orphan medicines, oncology treatments and highly targeted interventions are increasingly designed for smaller, more specific patient populations.

  • Comparator sourcing: the hidden complexity behind a single IMP line item

    An estimated two-thirds of clinical trials involve a comparator drug or co-therapy.

  • What is a managed access program? A pharmacist’s perspective

    A managed access program connects patients with medicines before PBS listing or standard supply. Here is how they work in Australia.

    Privacy Overview

    This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.